Status:

COMPLETED

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Lead Sponsor:

Pfizer

Conditions:

Healthy Participants

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The purpose of the study is to evaluate the effect of a low-fat and high-fat meal on the medicine called PF-07284890 following three single doses PF-07284890. The study will include male participants ...

Eligibility Criteria

Inclusion

  • Females of non-childbearing potential and males who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs.
  • Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).

Exclusion

  • Evidence or history of clinically significant uveitis, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), including any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  • Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).

Key Trial Info

Start Date :

June 17 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 16 2022

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT05349864

Start Date

June 17 2022

End Date

September 16 2022

Last Update

March 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New Haven Clinical Research Unit

New Haven, Connecticut, United States, 06511